Managed care has sent orthopedics companies searching for new ways to lower or justify the costs of bone-repair and replacement. Surgeons have lost the freedom to select favorite products and now look to the bottom line. Companies are trying to use molecular biology and materials advances to develop products that will look and act like natural bone, and so produce better, longer-lasting healing. Yet safety and liability concerns, and memories of past disappointments, are keeping financiers skeptical.